The Chemours Company

Quarterly Financial Information

November 2, 2018

Safe Harbor Statement

This presentation contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," “will,” "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance, business plans, prospects, targets, goals and commitments, capital investments and projects, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, and our outlook for net sales, Adjusted EBITDA, Adjusted EPS, Free Cash Flow, and Return on Invested Capital, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2017. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

Non-GAAP Financial Measures

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (“GAAP”). Within this presentation, we may make reference to Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Return on Invested Capital (ROIC) and Net Leverage Ratio which are non-GAAP financial measures. The company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making.

Management uses Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, ROIC and Net Leverage Ratio to evaluate the company’s performance excluding the impact of certain noncash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Accordingly, the company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the company’s operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the company’s financial statements and footnotes contained in the documents that the company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the company in this press release may be different from the methods used by other companies. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, “Reconciliation of Non-GAAP Financial Measures to GAAP Financial Measures” and materials posted to the company’s website at investors.chemours.com.

Chemours™

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Dollars in millions, except per share amounts)

	YTD* 2018	3Q18	2Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Net sales	**$ 5,174**	$ 1,628	$ 1,816	$ 1,730	**$ 6,183**	$ 1,575	$ 1,584	$ 1,588	$ 1,437	**$ 5,400**	$ 1,322	$ 1,398	$ 1,383	$ 1,297
Cost of goods sold	**3,603**	1,151	1,259	1,193	**4,438**	1,090	1,119	1,150	1,081	**4,297**	1,023	1,058	1,118	1,100
Gross profit	**1,571**	477	557	537	**1,745**	485	465	438	356	**1,103**	299	340	265	197
Selling, general, and administrative expense	**466**	163	161	143	**626**	165	153	164	150	**946**	480	151	178	135
Research and development expense	**61**	20	20	20	**81**	20	20	21	19	**81**	20	19	17	23
Restructuring, asset-related, and other charges	**32**	12	10	10	**57**	26	8	6	12	**170**	25	60	67	17
Total other operating expenses	**559**	195	191	173	**764**	211	181	191	181	**1,197**	525	230	262	175
Equity in earnings of affiliates	**32**	10	10	12	**33**	7	9	10	7	**29**	12	9	4	5
Interest expense, net	**(148)**	(47)	(48)	(52)	**(214)**	(54)	(55)	(54)	(51)	**(213)**	(56)	(51)	(50)	(57)
Loss on extinguishment of debt	**(38)**	—	(38)	—	**(1)**	—	—	(1)	—	**—**	—	—	—	—
Other income (expense), net	**115**	24	33	57	**113**	37	12	23	42	**267**	(3)	166	2	100
Income (loss) before income taxes	**973**	269	323	381	**912**	264	250	225	173	**(11)**	(273)	234	(41)	70
Provision for (benefit from) income taxes	**119**	(6)	41	84	**165**	36	43	64	22	**(18)**	(43)	30	(23)	19
Net income (loss)	**854**	275	282	297	**747**	228	207	161	151	**7**	(230)	204	(18)	51
Less: Net income attributable to non-controlling interests	**1**	—	1	—	**1**	—	—	—	1	**—**	—	—	—	—
Net income (loss) attributable to Chemours	**$ 853**	$ 275	$ 281	$ 297	**$ 746**	$ 228	$ 207	$ 161	$ 150	**$ 7**	$ (230)	$ 204	$ (18)	$ 51
Per share data														
Basic earnings (loss) per share of common stock	**$ 4.77**	$ 1.56	$ 1.58	$ 1.63	**$ 4.04**	$ 1.23	$ 1.12	$ 0.87	$ 0.82	**$ 0.04**	$ (1.26)	$ 1.12	$ (0.10)	$ 0.28
Diluted earnings (loss) per share of common stock	**4.62**	$ 1.51	1.53	1.58	**3.91**	1.19	1.08	0.84	0.79	**0.04**	(1.26)	1.11	(0.10)	0.28
Dividends per share of common stock	**0.42**	$ 0.25	0.17	—	**0.29**	0.20	0.03	0.03	0.03	**0.12**	0.03	0.03	0.03	0.03

* Note: Individual quarters may not sum to the full year and year-to-date amounts due to rounding.

Chemours

CONSOLIDATED BALANCE SHEETS
(Dollars in millions, except per share amounts)

	(Unaudited) September 30, 2018	December 31, 2017	December 31, 2016
Assets			
Current assets:			
Cash and cash equivalents	$ 1,275	$ 1,556	$ 902
Accounts and notes receivable, net	998	919	807
Inventories	1,086	935	767
Prepaid expenses and other	89	83	77
Total current assets	3,448	3,493	2,553
Property, plant, and equipment	8,885	8,511	7,997
Less: Accumulated depreciation	(5,678)	(5,503)	(5,213)
Property, plant, and equipment, net	3,207	3,008	2,784
Goodwill and other intangible assets, net	187	166	170
Investments in affiliates	179	173	136
Other assets	491	453	417
Total assets	$ 7,512	$ 7,293	$ 6,060
Liabilities			
Current liabilities:			
Accounts payable	$ 1,123	$ 1,075	$ 884
Current maturities of long-term debt	14	15	15
Other accrued liabilities	561	558	872
Total current liabilities	1,698	1,648	1,771
Long-term debt, net	3,985	4,097	3,529
Deferred income taxes	220	208	132
Other liabilities	463	475	524
Total liabilities	6,366	6,428	5,956
Commitments and contingent liabilities			
Equity			
Common stock (par value $0.01 per share; 810,000,000 shares authorized)	2	2	2
Treasury stock at cost	(636)	(116)	—
Additional paid-in capital	856	837	789
Retained earnings (accumulated deficit)	1,358	579	(114)
Accumulated other comprehensive loss	(440)	(442)	(577)
Total Chemours stockholders' equity	1,140	860	100
Non-controlling interests	6	5	4
Total equity	1,146	865	104
Total liabilities and equity	$ 7,512	$ 7,293	$ 6,060

Chemours

SEGMENT NET SALES (UNAUDITED)
(Dollars in millions)

	LTM* 3Q18	3Q18	2Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Fluoroproducts	$ 2,871	$ 682	$ 801	$ 732	$ 2,654	$ 656	$ 637	$ 710	$ 652	$ 2,264	$ 569	$ 591	$ 573	$ 531
Chemical Solutions	586	155	153	144	571	134	148	149	139	772	130	182	214	245
Titanium Technologies	3,292	791	862	854	2,958	785	799	729	646	2,364	623	625	596	521
TOTAL CHEMOURS	$ 6,749	$ 1,628	$ 1,816	$ 1,730	$ 6,183	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 5,400	$ 1,322	$ 1,398	$ 1,383	$ 1,297

SEGMENT ADJUSTED EBITDA (UNAUDITED)
(Dollars in millions)

	LTM* 3Q18	3Q18	2Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Fluoroproducts	$ 777	$ 182	$ 230	$ 206	$ 669	$ 159	$ 158	$ 197	$ 155	$ 445	$ 111	$ 143	$ 105	$ 85
Chemical Solutions	71	24	16	11	57	20	18	7	12	39	9	9	11	10
Titanium Technologies	1,118	268	295	294	862	261	249	193	159	466	157	144	111	54
Corporate and Other	(172)	(39)	(44)	(43)	(166)	(46)	(44)	(36)	(41)	(128)	(38)	(28)	(40)	(21)
TOTAL CHEMOURS	$ 1,794	$ 435	$ 497	$ 468	$ 1,422	$ 394	$ 381	$ 361	$ 285	$ 822	$ 239	$ 268	$ 187	$ 128

SEGMENT ADJUSTED EBITDA MARGIN (UNAUDITED)

	LTM* 3Q18	3Q18	2Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Fluoroproducts	27.1%	26.7%	28.7%	28.1%	25.2%	24.2%	24.8%	27.7%	23.8%	19.7%	19.5%	24.2%	18.3%	16.0%
Chemical Solutions	12.1%	15.5%	10.5%	7.6%	10.0%	14.9%	12.2%	4.7%	8.6%	5.1%	6.9%	4.9%	5.1%	4.1%
Titanium Technologies	34.0%	33.9%	34.2%	34.4%	29.1%	33.2%	31.2%	26.5%	24.6%	19.7%	25.2%	23.0%	18.6%	10.4%
Corporate and Other	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
TOTAL CHEMOURS	26.6%	26.7%	27.4%	27.1%	23.0%	25.0%	24.1%	22.7%	19.8%	15.2%	18.1%	19.2%	13.5%	9.9%

* Note: Individual quarters may not sum to the last twelve months (LTM) or full year amounts due to rounding.

Chemours™

SEGMENT NET ASSETS
(Dollars in millions)

	Full Year 2017	Full Year 2016
Fluoroproducts	$ 1,842	$ 1,400
Chemical Solutions (1)	460	292
Titanium Technologies	1,785	1,513
Corporate and Other	(3,222)	(3,101)
TOTAL CHEMOURS	$ 865	$ 104

(1) As of December 31, 2016, Chemical Solutions' net assets were reduced by approximately $415 in connection with the sales of our Clean & Disinfect and Sulfur businesses during 2016. For further details, refer to Note 7 of the Consolidated Financial Statements included in our Annual Report on Form 10-K as of and for the year ended December 31, 2017.

Chemours™

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

(Dollars in millions, except per share amounts)

RECONCILIATION OF NET INCOME (LOSS) ATTRIBUTABLE TO CHEMOURS TO ADJUSTED NET INCOME AND ADJUSTED EBITDA

	LTM* 3Q18	3Q18	2Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Net income (loss) attributable to Chemours	**$ 1,081**	$ 275	$ 281	$ 297	**$ 746**	$ 228	$ 207	$ 161	$ 150	**$ 7**	$ (230)	$ 204	$ (18)	$ 51
Non-operating pension and other post-retirement employee benefit income	**(28)**	(4)	(7)	(7)	**(34)**	(10)	(7)	(10)	(8)	**(20)**	(1)	(5)	(7)	(7)
Exchange losses (gains), net	**4**	6	(2)	—	**(3)**	—	4	(2)	(5)	**57**	20	17	14	6
Restructuring and other charges	**57**	12	9	10	**57**	26	8	6	12	**51**	11	14	9	17
Asset-related and other charges (1)	**1**	—	1	—	**3**	—	1	2	—	**124**	14	46	63	—
Loss on extinguishement of debt	**38**	—	38	—	**1**	—	—	1	—	**—**	—	—	—	—
(Gain) loss on sale of assets or businesses (2)	**(53)**	—	(3)	(42)	**(22)**	(8)	—	2	(16)	**(254)**	3	(169)	1	(89)
Transaction costs (3)	**9**	—	9	—	**3**	—	1	2	—	**19**	1	2	12	3
Legal and other charges (4,7)	**48**	34	10	4	**18**	—	7	10	7	**359**	336	5	13	5
Adjustments made to income taxes (5,8)	**(57)**	(41)	(8)	(5)	**(25)**	(3)	(11)	(3)	(10)	**18**	18	—	—	—
(Benefit from) provision for income taxes relating to reconciling items (6,8)	**(20)**	(11)	(14)	9	**(16)**	(4)	(7)	(5)	1	**(148)**	(139)	(5)	(5)	1
Adjusted Net Income	**1,080**	271	314	266	**728**	229	203	164	131	**213**	33	109	82	(13)
Net income attributable to non-controlling interests	**1**	—	1	—	**1**	—	—	—	1	**—**	—	—	—	—
Interest expense, net	**201**	47	48	52	**214**	54	55	54	51	**213**	56	51	50	57
All remaining depreciation and amortization (7)	**281**	71	71	70	**273**	69	62	71	71	**284**	72	73	73	66
All remaining provision for (benefit from) income taxes (8)	**231**	46	63	80	**206**	42	61	72	31	**112**	78	35	(18)	18
Adjusted EBITDA	**$ 1,794**	$ 435	$ 497	$ 468	**$ 1,422**	$ 394	$ 381	$ 361	$ 285	**$ 822**	$ 239	$ 268	$ 187	$ 128
Adjusted basic earnings per share of common stock	**$ 5.99**	$ 1.54	$ 1.77	$ 1.46	**$ 3.93**	$ 1.23	$ 1.09	$ 0.89	$ 0.72	**$ 1.17**	$ 0.18	$ 0.60	$ 0.45	$ (0.07)
Adjusted diluted earnings per share of common stock	**5.80**	1.49	1.71	1.41	**3.81**	1.19	1.06	0.86	0.70	**1.16**	0.18	0.59	0.45	(0.07)

(1) The year ended December 31, 2016 includes pre-tax impairment charges of $13 and $58 associated with the sales of the Company's corporate headquarters building located in Wilmington, Delaware and Sulfur business, respectively, and $48 in pre-tax impairment charges associated with the Company's aniline facility in Pascagoula, Mississippi, as well as certain other asset write-offs.

(2) For the three months ended June 30, 2018, gain on sale includes a $3 gain associated with the sale of the Company's East Chicago, Indiana site. For the three months ended March 31, 2018, gain on sale includes a $42 gain associated with the sale of the Company's Linden, New Jersey site. The year ended December 31, 2017 includes gains of $13 and $12 associated with meeting certain milestones in connection with the Company's sale of land in Repauno, New Jersey, and for the sale of the Company's Edge Moor, Delaware plant site, respectively, net of certain losses on other disposals. The year ended December 31, 2016 includes gains of $169 and $89 associated with the sales of the Company's C&D business and aniline facility in Beaumont, Texas, respectively.

(3) Includes costs associated with the Company's debt transactions, as well as accounting, legal, and bankers' transaction costs incurred in connection with the Company's strategic initiatives, which includes pre-sale transaction costs incurred in connection with the sales of the C&D and Sulfur businesses during 2016.

(4) Includes litigation settlements, PFOA drinking water treatment accruals, acquisition-related intangible asset amortization, and other charges, including the $30 estimated liability for our Fayetteville, North Carolina site for the three and nine months ended September 30, 2018, the latter of which is included as a component of selling, general and administrative expense in our consolidated statements of operations. The year ended December 31, 2016 includes $335 in litigation accruals associated with the PFOA MDL Settlement.

(5) Includes the removal of certain discrete income tax impacts within the Company's provision for (benefit from) income taxes. For 2018, the adjustments made to income taxes includes the following: $19 in tax benefits primarily related to the filing of the Company's 2017 U.S. tax return and the associated adjustments including the revaluation of deferred tax assets and liabilities as a result of the reduced corporate tax rate and other associated adjustments, $17 in tax benefits for the reversal of the Company's valuation allowance on foreign tax credit carryforwards due to changes in normal business operations, $4 in windfall tax benefits on the Company's share-based payments, and $1 in tax benefits resulting from unrealized losses on foreign exchange rates related to toll charges pursuant to U.S. tax reform. For 2017, the adjustment is primarily attributable to a benefit of $20 related to windfall tax benefits on the Company's share-based payments, the reversal of a reserve for uncertain tax positions of $6, and a benefit for the net impact of U.S. tax reform of $3, which are partially offset by foreign exchange gains and losses of $5. For 2016, the adjustment of $18 related entirely to tax implications of foreign exchange gains and losses.

(6) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and include both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

(7) The total amount of depreciation and amortization, including acquisition-related intangible asset amortization included in legal and other charges above, reconciles to the amount reported in the statements of cash flows.

(8) The total provision for (benefit from) income taxes reconciles to the amount reported in the consolidated statements of operations.

* Note: Individual quarters may not sum to the last twelve months (LTM) or full year amounts due to rounding.

RECONCILIATION OF FREE CASH FLOWS

	LTM* 3Q18	3Q18	2Q18	1Q18	Full Year* 2017	4Q17	3Q17	2Q17	1Q17	Full Year* 2016	4Q16	3Q16	2Q16	1Q16
Cash provided by operating activities (1)	**$ 1,184**	$ 342	$ 343	$ 196	**$ 640**	$ 303	$ 112	$ 184	$ 41	**$ 594**	$ 269	$ 199	$ 90	$ 36
Less: Purchases of property, plant, and equipment	**(509)**	(116)	(126)	(102)	**(411)**	(165)	(108)	(69)	(69)	**(338)**	(103)	(67)	(79)	(89)
Free Cash Flows (1)	**$ 675**	$ 226	$ 217	$ 94	**$ 229**	$ 138	$ 4	$ 115	$ (28)	**$ 256**	$ 166	$ 132	$ 11	$ (53)

(1) Cash provided by operating activities for the year ended December 31, 2017 includes $335 in payments related to the PFOA MDL Settlement. Cash provided by operating activities for the year ended December 31, 2016 includes $190 in prepayments from DuPont, of which $58 was outstanding at December 31, 2016. The DuPont prepayment was fully utilized during the year ended December 31, 2017.

* Note: Individual quarters may not sum to the last twelve months (LTM) or full year amounts due to rounding.

Chemours

ADJUSTED NET INCOME AND ADJUSTED EBITDA RECONCILING ITEMS BY FINANCIAL STATEMENT LINE ITEM (UNAUDITED)

(Dollars in millions)

		3Q18				3Q17			
Reconciling Items	Statements of Operations Categories (1)	Total	COGS	SG&A	Other	Total	COGS	SG&A	Other
Non-operating pension and other post-retirement employee benefit income	Other income, net	**$ (4)**	$ —	$ —	$ (4)	**$ (7)**	$ —	$ —	$ (7)
Exchange gains, net	Other income, net	**6**	—	—	6	**4**	—	—	4
Restructuring and other charges	Restructuring	**12**	—	—	12	**8**	—	—	8
Asset-related and other charges	Restructuring / COGS	**—**	—	—	—	**1**	—	—	1
Loss on extinguishment of debt	Loss on extinguishment	**—**	—	—	—	—	—	—	—
(Gain) loss on sale of assets or businesses	Other income, net	**—**	—	—	—	—	—	—	—
Transaction costs	SG&A	**—**	—	—	—	**1**	—	1	—
Legal and other charges	SG&A	**34**	—	34	—	**7**	—	7	—
Adjustments made to income taxes	Provision for income taxes	**(41)**	—	—	(41)	(11)	—	—	(11)
Benefit from income taxes relating to reconciling items	Provision for income taxes	**(11)**	—	—	(11)	**(7)**	—	—	(7)
Total Adjusted Net Income reconciling items		**(4)**	**—**	**34**	**(38)**	**(4)**	**—**	**8**	**(12)**
Net income attributable to non-controlling interests	NCI	**—**	—	—	—	**—**	—	—	—
Interest expense, net	Interest expense, net	**47**	—	—	47	**55**	—	—	55
All remaining depreciation and amortization	COGS / SG&A	**71**	65	6	—	**62**	56	6	—
All remaining provision for income taxes	Provision for income taxes	**46**	—	—	46	**61**	—	—	61
Total Adjusted EBITDA reconciling items		**$ 160**	**$ 65**	**$ 40**	**$ 55**	**$ 174**	**$ 56**	**$ 14**	**$ 104**

(1) Abbreviated Statements of Operations Categories represent the following financial statement line items in the statements of operations:
- COGS - Cost of goods sold
- SG&A - Selling, general, and administrative expense
- Restructuring - Restructuring, asset-related, and other charges
- NCI - Net income attributable to non-controlling interests
- Loss on extinguishment - Loss on extinguishment of debt

RETURN ON INVESTED CAPITAL RECONCILIATION (UNAUDITED)

(Dollars in millions)

	Twelve Months Ended		Year Ended	
	September 30, 2018	September 30, 2017	December 31, 2017	December 31, 2016
Adjusted EBITDA (1)	$ 1,794	$ 1,266	$ 1,422	$ 822
Less: Depreciation and amortization (1)	(281)	(276)	(273)	(284)
Adjusted EBIT	1,513	990	1,149	538
Total debt	3,999	4,095	4,112	3,544
Total equity	1,146	805	865	104
Less: Cash and cash equivalents	(1,275)	(1,535)	(1,556)	(902)
Invested capital, net	$ 3,870	$ 3,365	$ 3,421	$ 2,746
Average invested capital (2)	$ 3,637	$ 3,102	$ 3,157	$ 3,419
Return on Invested Capital	41.6%	31.9%	36.4%	15.7%

(1) Based on amounts for the trailing 12 months ended September 30, 2018 and 2017 and December 31, 2017 and 2016. Reconciliations of Adjusted EBITDA to net income (loss) attributable to Chemours are provided on quarterly and full year bases. See the preceding tables for the reconciliation of Adjusted EBITDA to net income attributable to Chemours for the three months ended September 30, 2018 and 2017 and for the years ended December 31, 2017 and 2016.

(2) Average invested capital is based on a five-quarter trailing average of invested capital, net.